DE69226431T2 - Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor - Google Patents
Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptorInfo
- Publication number
- DE69226431T2 DE69226431T2 DE69226431T DE69226431T DE69226431T2 DE 69226431 T2 DE69226431 T2 DE 69226431T2 DE 69226431 T DE69226431 T DE 69226431T DE 69226431 T DE69226431 T DE 69226431T DE 69226431 T2 DE69226431 T2 DE 69226431T2
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibodies
- antibodies against
- receptor
- specific monoclonal
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68124591A | 1991-04-05 | 1991-04-05 | |
PCT/US1992/002674 WO1992017505A1 (en) | 1991-04-05 | 1992-04-03 | Monoclonal antibodies to stem cell factor receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69226431D1 DE69226431D1 (de) | 1998-09-03 |
DE69226431T2 true DE69226431T2 (de) | 1999-04-22 |
Family
ID=24734435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69226431T Expired - Fee Related DE69226431T2 (de) | 1991-04-05 | 1992-04-03 | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
Country Status (10)
Country | Link |
---|---|
US (5) | US5489516A (de) |
EP (1) | EP0578774B1 (de) |
JP (1) | JP3213314B2 (de) |
AT (1) | ATE169031T1 (de) |
CA (1) | CA2107553C (de) |
DE (1) | DE69226431T2 (de) |
DK (1) | DK0578774T3 (de) |
ES (1) | ES2118820T3 (de) |
HK (1) | HK1008827A1 (de) |
WO (1) | WO1992017505A1 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
RU2212411C2 (ru) * | 1989-10-16 | 2003-09-20 | Эмджен Инк. | Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты) |
EP0578774B1 (de) * | 1991-04-05 | 1998-07-29 | The Board Of Regents Of The University Of Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
EP0548867A2 (de) * | 1991-12-23 | 1993-06-30 | Yeda Research And Development Co. Ltd. | Wasserlöslicher Stammzellenfaktor-Rezeptor |
FR2700471B1 (fr) * | 1993-01-21 | 1995-04-07 | Pasteur Merieux Serums Vacc | Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus. |
US5911988A (en) * | 1995-04-28 | 1999-06-15 | Bayer Corporation | Method for treating asthma using SCF antibody |
US5824789A (en) * | 1995-06-07 | 1998-10-20 | Systemix, Inc. | Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof |
DE19600589C1 (de) | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
SE9803712L (sv) * | 1998-10-29 | 1999-12-20 | Henrik Willers | Förfarande och anordning för förankring av en boj |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
EP2329847B1 (de) * | 2000-03-06 | 2016-11-02 | University of Kentucky Research Foundation | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
US20050064587A1 (en) * | 2001-09-07 | 2005-03-24 | Lawrence Rosenberg | Pancreatic small cells and uses thereof |
US20030175818A1 (en) * | 2002-03-15 | 2003-09-18 | Ross Amelia A. | Devices and methods for isolating and recovering target cells |
US7754155B2 (en) * | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
ES2438965T3 (es) * | 2002-04-23 | 2014-01-21 | Roger Williams Hospital | Composiciones y métodos para administrar células madre |
US7577297B2 (en) * | 2002-12-16 | 2009-08-18 | Canon Kabushiki Kaisha | Pattern identification method, device thereof, and program thereof |
WO2005067889A1 (en) | 2003-12-30 | 2005-07-28 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh |
AU2006295340B2 (en) * | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
EP2783700A1 (de) * | 2006-09-07 | 2014-10-01 | Stemline Therapeutics, Inc. | Auf Krebsstammzellen gerichtete Krebstherapie |
EP3255061B1 (de) | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selektive immundepletion einer endogenen stammzellennische zur transplantation |
WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
BR122021020041B1 (pt) | 2010-09-28 | 2023-03-07 | Amylin Pharmaceuticals, Llc | Polipeptídeo quimérico, seu uso e composição que o compreende |
WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
DK3381943T3 (da) | 2012-07-25 | 2022-05-16 | Celldex Therapeutics Inc | Anti-kit-antistoffer og anvendelser deraf |
NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
WO2015050959A1 (en) * | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CN105793411B (zh) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | 生物反应器中的细胞扩增 |
JP6783143B2 (ja) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | 培地の受動的補充 |
JP6768639B2 (ja) | 2014-05-23 | 2020-10-21 | セルデックス セラピューティクス,インコーポレーテッド | 好酸球又はマスト細胞関連障害の治療 |
US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
WO2016154588A1 (en) | 2015-03-25 | 2016-09-29 | Children's Hospital Medical Center | Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
CN109415696A (zh) | 2016-05-25 | 2019-03-01 | 泰尔茂比司特公司 | 细胞扩增 |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
AU2017204125B1 (en) | 2016-06-17 | 2017-10-26 | Crispr Therapeutics Ag | Compositions and methods for the depletion of cd117+ cells |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (de) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Zellexpansion |
WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
AU2022409748A1 (en) | 2021-12-16 | 2024-05-23 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd117 for use in cell therapy |
WO2024008910A1 (en) | 2022-07-07 | 2024-01-11 | Cimeio Therapeutics Ag | Antibodies targeting cd117 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965204A (en) * | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5081030A (en) * | 1989-04-25 | 1992-01-14 | The Johns Hopkins University | Release of cells from affinity matrices |
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
EP0578774B1 (de) * | 1991-04-05 | 1998-07-29 | The Board Of Regents Of The University Of Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
-
1992
- 1992-04-03 EP EP92910836A patent/EP0578774B1/de not_active Expired - Lifetime
- 1992-04-03 DE DE69226431T patent/DE69226431T2/de not_active Expired - Fee Related
- 1992-04-03 DK DK92910836T patent/DK0578774T3/da active
- 1992-04-03 ES ES92910836T patent/ES2118820T3/es not_active Expired - Lifetime
- 1992-04-03 AT AT92910836T patent/ATE169031T1/de not_active IP Right Cessation
- 1992-04-03 JP JP51001792A patent/JP3213314B2/ja not_active Expired - Fee Related
- 1992-04-03 WO PCT/US1992/002674 patent/WO1992017505A1/en active IP Right Grant
- 1992-04-03 CA CA002107553A patent/CA2107553C/en not_active Expired - Fee Related
-
1993
- 1993-01-29 US US08/011,078 patent/US5489516A/en not_active Expired - Lifetime
-
1994
- 1994-06-07 US US08/255,193 patent/US5922847A/en not_active Expired - Fee Related
-
1995
- 1995-05-24 US US08/449,139 patent/US5906938A/en not_active Expired - Fee Related
- 1995-06-05 US US08/462,638 patent/US5919911A/en not_active Expired - Fee Related
-
1998
- 1998-07-31 HK HK98109574A patent/HK1008827A1/xx not_active IP Right Cessation
-
1999
- 1999-07-13 US US09/352,466 patent/US20020018775A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH06506833A (ja) | 1994-08-04 |
US20020018775A1 (en) | 2002-02-14 |
EP0578774B1 (de) | 1998-07-29 |
ATE169031T1 (de) | 1998-08-15 |
DK0578774T3 (da) | 1999-04-26 |
ES2118820T3 (es) | 1998-10-01 |
EP0578774A4 (en) | 1995-11-15 |
HK1008827A1 (en) | 1999-05-21 |
US5922847A (en) | 1999-07-13 |
JP3213314B2 (ja) | 2001-10-02 |
WO1992017505A1 (en) | 1992-10-15 |
EP0578774A1 (de) | 1994-01-19 |
CA2107553C (en) | 2001-07-31 |
DE69226431D1 (de) | 1998-09-03 |
CA2107553A1 (en) | 1992-10-06 |
US5906938A (en) | 1999-05-25 |
US5489516A (en) | 1996-02-06 |
US5919911A (en) | 1999-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE169031T1 (de) | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor | |
DK0817847T3 (da) | IL-17-receptor | |
UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
FI972945A (fi) | Antigeenien antamiseen soveltuvia koostumuksia | |
MY122262A (en) | Lh-rh peptide analogues their uses and pharmaceutical compositions containing them | |
DE69824029D1 (de) | Bicyclische kinase inhibitoren | |
DE69216532D1 (de) | Azidfreie gaserzeugende Zusammensetzungen | |
ES8704946A1 (es) | Un procedimiento para la preparacion de triazolobenzodiazefinas. | |
YU394A (sh) | Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu | |
MX9801890A (es) | Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen. | |
YU13392A (sh) | ANTITELA NA HUMANI RECEPTOR ZA IgE | |
ATE189122T1 (de) | Monoklonale anti-idiotypische anti - ca125 antikörper und sie enthaltende pharmazeutische zusammensetzung | |
BR9806193A (pt) | Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm | |
ATE188692T1 (de) | Fibrinogenrezeptorantagonisten | |
FI20095269A (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
ATE122895T1 (de) | Monoklonale antikörper gegen den interleukin 2- rezeptor. | |
EA199700223A1 (ru) | Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции | |
DE69431662T2 (de) | Stabilisierte tablettenformulierung | |
MY118946A (en) | Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides | |
ATE217619T1 (de) | Endothelin-rezeptor-antagonisten | |
ATE252636T1 (de) | Klonierung und expression von dem beta app-c100 rezeptor | |
DE69623464D1 (de) | Modifizierte kojibioside analoge | |
IL119412A (en) | Gonadotropins and pharmaceutical compositions containing them | |
DE69614552T2 (de) | MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE | |
DE69010897D1 (de) | Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |